MedTrace Logo

FLACS vs Phaco in Shallow Anterior Chamber

NCT03587909 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2018-07-16

No results posted yet for this study

Summary

Phacoemulsification in eyes with a shallow anterior chamber (ACD \< 2.2mm) presents with problems of safe access to the cataract and increased vulnerability of the endothelium and a higher tendency of complications such as descemet's detachment and iris prolapse. A shallow anterior chamber is also responsible for the high incidence of glaucoma and postoperative complications after cataract surgery. Femtosecond assisted cataract surgery has made cataract surgery safer and more predictable. The effective phacoemulsification time and intra-operative manipulation is greatly reduced in FLACS. However phacoemulsification still remains the most widely performed cataract surgery around the world. Post-operative outcomes after phacoemulsification in patients having shallow anterior chamber have been extensively reported in literature over the years.

There is no head to head comparison in terms of intraoperative performance and post-operative outcomes between FLACS and phacoemulsification in eyes with shallow anterior chamber.

The aim is to compare the intra-operative performance and post-operative outcomes in eyes undergoing femtosecond laser assisted cataract surgery versus eyes undergoing phacoemulsification in eyes having shallow anterior chamber.

The study will bring an understanding on the question: Do patients undergoing Femtosecond laser assisted cataract surgery behave differently from those undergoing phacoemulsification?

Conditions

  • Cataract Surgery
  • Shallow Anterior Chamber
  • Phacoemulsification

Interventions

PROCEDURE

Phacoemulsification Cataract SUrgery

Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)

PROCEDURE

Femtosecond Cataract Surgery

Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm

Sponsors & Collaborators

  • Iladevi Cataract and IOL Research Center

    lead OTHER

Principal Investigators

  • Abhay Vasavada, MS,FRCS · Iladevi Cataract & IOL Research Centre, Ahmedabad

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2017-12-01
Completion
2018-01-15

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03587909 on ClinicalTrials.gov